

Biometric covariates and outcome in COVID-19 patients: Are we looking close enough?

Appendix

Influence of baseline values

We checked differential baseline values across the survivors / non-survivors in each subcohort, compared to all survivors and non-survivors. Systematic differential expression in a subcohort compared to all MV patients are given in table 1.

Table 1: Baseline values, which are increased / decreased within the respective subcohort

Bilirubin	Decreased (p < 0.05)	Survivors [Low BMI/high age]
I:E	Increased (p < 0.05)	Survivors [Low BMI/high age]
Creatinine	Increased (p < 0.05)	Survivors [Low BMI/high age]
Tidal volume	Increased (p < 0.05)	Survivors [High BMI/high age]
SpO2	Increased (p < 0.05)	Non-Survivors [Intermediate BMI/low age]

Surprisingly, the only significant difference in subcohort 3 is SpO2 for Non-Survivors despite the highly significant deviation of mortality.

Influence of comorbidities

In analogy to differential levels of baseline diagnostic parameters, we assessed enrichment of comorbidities between survivors and non-survivors for each subcohort compared to survivors / non-survivors in all MV patients.

Comorbidities, which are enriched / suppressed within the survivor/ non-survivor populations of the 6 subcohorts are shown in table 2:

Table 2: Comorbidities, which are enriched / suppressed within the respective subcohort

Chronic Heart Failure	Enriched (p < 0.05)	Survivors [High BMI/low age]
Diabetes Mellitus	Enriched (p < 0.01)	Survivors [High BMI/low age]
Diseases of blood and blood forming organs	Suppressed (p < 0.05)	Non-survivors [Low BMI/high age]
Diseases of the digestive system	Suppressed (p < 0.05)	Non-survivors [Intermediate BMI/high age]
Diseases of the digestive system	Enriched (p < 0.05)	Non-survivors [High BMI/low age]
Sepsis	Suppressed (p < 0.05)	Non-survivors [Low BMI/high age]

As the enrichment analysis didn't result in neither highly significant enrichments of comorbidities nor difference in diagnostic baseline levels, corrections with respect to multiple testing show no robust significance. Hence, we cannot claim univariate explanations of the observed patterns in morbidity.

Enrichment analysis of comorbidities in non-MV patients compared to MV patients

Assessing the enrichment (Bonferroni-corrected $p < 0.01$) of comorbidities in MV-survivor / non-survivor population compared to non-MV population, we found comorbidities, which are strongly enriched in MV cohort (independent from survival) compared to non-MV patient cohort:

Table 3: Enrichment of comorbidities in MV population compared to non-MV population

	Non-MV	MV
Diseases of the blood and blood-forming organs	$\log_{10}(p) = -3.48$	$\log_{10}(p) = -3.73$
Diseases of the genitourinary system	$\log_{10}(p) = -2.62$	$\log_{10}(p) = -3.98$
Diseases of the skin and subcutaneous tissue	$\log_{10}(p) = -3.57$	$\log_{10}(p) = -2.22$
Endocrine, nutritional and metabolic diseases	$\log_{10}(p) = -3.83$	$\log_{10}(p) = -3.3$
Symptoms, signs and abnormal clinical and laboratory finding	$\log_{10}(p) = -3.92$	$\log_{10}(p) = -3.98$
Sepsis	$\log_{10}(p) = -4.8$	$\log_{10}(p) = -6.3$

Apparently, Sepsis is a syndrome, which is highly significantly enriched in MV-patient cohort compared to non-MV cohorts, both for survivors and non-survivors.